You just read:

BioMarin Provides 2 Years of Clinical Data in 6e13 vg/kg Dose from Ongoing Phase 1/2 Study in Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at World Federation of Hemophilia 2018 World Congress

News provided by

BioMarin Pharmaceutical Inc.

May 22, 2018, 07:30 ET